Transplant immunology最新文献

{"title":"Induction outcomes in adult kidney transplantation: Two decades of UNOS data analysis","authors":"Emmanuel Aydin-Ghormoz ,&nbsp;Jorge Ortiz ,&nbsp;Kathryn Schubauer ,&nbsp;Naoru Koizumi ,&nbsp;Meng-Hao Li ,&nbsp;Geovani Faddoul","doi":"10.1016/j.trim.2025.102198","DOIUrl":"10.1016/j.trim.2025.102198","url":null,"abstract":"<div><h3>Objectives</h3><div>In the US, 92 % of kidney transplant recipients are treated with induction therapy. This analysis assesses the impact of induction immunosuppression on outcomes such as graft failure, patient mortality, and length of hospitalization.</div></div><div><h3>Material and methods</h3><div>Retrospective analysis of the UNOS database in adults who received a kidney transplant from January 2000 to June 2022. Analysis focused on induction regimens including anti-thymocyte globulin (ATG), alemtuzumab and basiliximab with maintenance immunosuppression of calcineurin inhibitors, mycophenolate with or without prednisone. Multivariable logistic regression was performed to identify factors correlating with outcomes. Kaplan-Meier product limit method assessed survival.</div></div><div><h3>Results</h3><div>Alemtuzumab correlated with increased graft failure in deceased-donor and living-donor kidney transplants (HR 1.075 [1.015–1.138] <em>p</em> = 0.013 and HR 1.096 [1.011–1.188] <em>p</em> = 0.026 respectively) and with increased mortality in living-donor kidney transplants (HR 1.215 [1.107–1.332] <em>p</em> &lt; 0.001). Steroids maintenance was associated with fewer acute rejections in both deceased-donor and living-donor kidney transplants (HR = 0.875 [0.84–0.90] <em>p</em> &lt; 0.001 and HR = 0.88 [0.83–0.93] <em>p</em> &lt; 0.001 respectively). Odds of CMV was lower with alemtuzumab. Induction with alemtuzumab was associated with shorter length of stay in both deceased-donor and living-donor kidney transplants and longer time to first hospitalization in living-donor kidney transplants compared to ATG.</div></div><div><h3>Conclusions</h3><div>Alemtuzumab correlated with shorter length of stay, fewer re-hospitalizations and less CMV infections. However, it was associated with higher odds of graft failure and mortality in adult kidney transplant recipients.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"89 ","pages":"Article 102198"},"PeriodicalIF":1.6,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143394700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determining the best premedication regimen to prevent rabbit anti-human thymocyte globulin infusion-associated reactions: A retrospective study comparing two hematopoietic stem cell transplant centers","authors":"Keven Vachon ,&nbsp;Marc-Antoine Tardif ,&nbsp;Étienne Paillé ,&nbsp;Marie-Helene Leblanc ,&nbsp;Guy Cantin ,&nbsp;Christopher Lemieux ,&nbsp;Geneviève Gallagher","doi":"10.1016/j.trim.2025.102178","DOIUrl":"10.1016/j.trim.2025.102178","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;Thymoglobulin® (ATG), a rabbit anti-human thymocyte globulin, is used in allogeneic hematopoietic stem cell transplantation (HSCT) mainly to prevent the development of graft-versus-host disease (GVHD). Three doses (ATG1, ATG2, and ATG3) are administered on separate days, apart from the graft day. Since infusion-associated reactions (IAR) are frequent, patients were treated with acetaminophen, antihistamine, and corticosteroids (CS) as premedication (PR); however, the best PR regimen remains to be defined.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;The study compared the incidence and severity of IAR related to ATG according to the different PR therapy. This descriptive retrospective cohort study included patients receiving ATG in two HSCT transplant centers (Hospitals A and B). The data cut-off was in March 2020, but the period of interest was different between the two hospitals to balance the two groups. Four PR regimens were compared, one from Hospital A (PR-A) and three from Hospital B (PR-B1, B2, and B3), which have changed twice in the last decade. Along with PR therapy, the indication and method of administration of ATG also differed between hospitals.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;A total of 132 patients were included from May 2011 to March 2020. Groups PR-A, B1, B2, and B3 had, respectively, 61, 22, 26, and 23 patients. Of them, 115 (87 %) had at least one IAR, and 86 (65 %) had at least one severe IAR during any ATG infusions. ATG3 had the lowest incidence of IAR (39 %), and it seemed better tolerated when given after graft infusion than before (32 % vs. 46 %, respectively; &lt;em&gt;p&lt;/em&gt; = 0.11). Almost three-quarters of patients had at least one IAR that occurred after the end of an ATG infusion, but there was less IAR with PR-B3 protocol where acetaminophen and diphenhydramine were regularly administered beyond ATG infusion. Hospital A used a progressive rate of infusion, but early IAR was seen compared to Hospital B (&lt;em&gt;p&lt;/em&gt; = 0.03), where a fixed rate was used. No direct association was found between the CS dose received and IAR incidence (&lt;em&gt;p&lt;/em&gt; = 0.21) or severity (&lt;em&gt;p&lt;/em&gt; = 0.61). However, there was a recurrent signal for less severe IAR in the PR-B3 group compared to its predecessors, B1 and B2 groups (&lt;em&gt;p&lt;/em&gt; = 0.12), and the key difference was an increased CS dose. The mean total CS therapy received was nearly double at Hospital A compared with Hospital B (1182 vs. 692 mg prednisone equivalent; &lt;em&gt;p&lt;/em&gt; &lt; 0.01). Fungal infection rate was higher in Hospital A compared to Hospital B (33 % vs. 13 %; &lt;em&gt;p&lt;/em&gt; &lt; 0.01). The infection rate correlated with a higher dose of CS received on days of ATG therapy (p &lt; 0.01).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;ATG3 given the day after HSCT appears to play a key role in reducing the incidence and severity of IAR. Infusion over six hours at a fixed rate was safe. Frequent, regular, and extended doses of acetaminophen and antihistamines b","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"89 ","pages":"Article 102178"},"PeriodicalIF":1.6,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143349513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of liver transplant mortality scales in a Mexican population","authors":"Alejandra Nuñez-Venzor ,&nbsp;Asya Zubillaga-Mares ,&nbsp;Aczel I. Sánchez-Cedillo ,&nbsp;Josué I. Olivares del Moral ,&nbsp;Carlos Florez-Zorrilla ,&nbsp;Elizabeth Buganza-Torio ,&nbsp;Francisco E. Alvarez-Bautista ,&nbsp;Mario Trejo-Avila ,&nbsp;Manuel Martínez-Meraz","doi":"10.1016/j.trim.2025.102185","DOIUrl":"10.1016/j.trim.2025.102185","url":null,"abstract":"<div><h3>Background</h3><div>Liver transplantation is the treatment of choice in patients with chronic liver disease and acute liver failure of any etiology. Scales such as the Survival Outcome Following Transplantation (SOFT) score and the Balance of Risk (BAR) score can be used to predict survival. In this study, we compared these scales in the Mexican population.</div></div><div><h3>Methods</h3><div>A cross-sectional analytical study was carried out in a Mexican third-level transplant center. The MELD, SOFT, and BAR scales were adopted. The ROC curves of the three predictive scores were constructed, and the areas under the curve were obtained and compared. A bivariate analysis and Cox regression were performed. Finally, a survival analysis was performed using Kaplan–Meier curves.</div></div><div><h3>Results</h3><div>We analyzed 123 liver transplant (LT) recipients. The bivariate analysis and Cox regression indicated that portal thrombosis, with an HR of 3.36 (IC 1.069–10.59, <em>p</em> = 0.038), and the number of red blood cells transfused, with an HR of 1.084 (CI 1.039–1.130, <em>p</em> &lt; 0.000), were significantly associated with mortality. The receiver height was a protective factor, with an HR of 0.001 (CI 0.000–0.761, <em>p</em> = 0.041). Regarding the Pearson correlation analysis, the BAR scale had a coefficient of 0.199 (<em>p</em> = 0.032) for transfusion, while the SOFT scale's correlation coefficients for cold ischemia and transfusion were 0.236 (<em>p</em> = 0.011) and 0.274 (<em>p</em> = 0.003), respectively, all indicating weak correlations. The areas under the curve (AUCs) of MELD, SOFT, and BAR in predicting 3-month mortality were 0.495 (<em>P</em> = 0.94), 0.608 (<em>p</em> = 0.129), and 0.502 (<em>p</em> = 0.97), respectively. Finally, in the survival analysis using Kaplan–Meier curves, an estimated mean survival period of 71.52 months was obtained, with a survival rate of 89.3 % at 30 days and 81.1 % at five years.</div></div><div><h3>Conclusion</h3><div>In this study, it was found that all three scales were deficient in discriminating among the outcomes obtained in the Mexican population.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"89 ","pages":"Article 102185"},"PeriodicalIF":1.6,"publicationDate":"2025-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143190620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of outcomes following subcutaneous or intravenous alemtuzumab administered prior to reduced intensity conditioning for transplantation in pediatric sickle cell disease","authors":"Alexandra Plavsa ,&nbsp;Tara Suresh ,&nbsp;Stuti Dalal ,&nbsp;Lucia Mirea ,&nbsp;Roberta H. Adams ,&nbsp;Shalini Shenoy ,&nbsp;Alexander Ngwube","doi":"10.1016/j.trim.2025.102179","DOIUrl":"10.1016/j.trim.2025.102179","url":null,"abstract":"<div><h3>Background</h3><div>Alemtuzumab-containing conditioning regimens are used for allogeneic hematopoietic stem cell transplantation (HSCT) to reduce acute and chronic graft-versus-host disease (GVHD) and the risk of graft rejection. Alemtuzumab is typically administered intravenously but is often accompanied by infusion-related side effects, including injection site reactions and anaphylaxis. Little is known about the routes of administration and if they differ in safety and efficacy in pediatric patients, especially when used in transplant conditioning.</div></div><div><h3>Objectives</h3><div>To compare adverse effects and efficacy outcomes between intravenous and subcutaneous alemtuzumab administration in pediatric patients with sickle cell disease who have undergone HSCT.</div></div><div><h3>Study design</h3><div>A retrospective cohort of 49 pediatric patients with sickle cell disease aged 4–16 years underwent HSCT and received either intravenous or subcutaneous alemtuzumab at St. Louis Children's Hospital or Phoenix Children's Hospital. The incidence of infusion-related reactions, neutrophil and platelet recovery, graft failure, and immune reconstitution were compared.</div></div><div><h3>Results</h3><div>We found that subcutaneous alemtuzumab administration elicited fewer infusion-related reactions than intravenously administered drug (<em>p</em> = 0.038). No significant differences in engraftment rates, graft failure rates, infectious complications, acute GVHD, and immune reconstitution were found between the two groups.</div></div><div><h3>Conclusion</h3><div>Subcutaneous administration of alemtuzumab for children undergoing transplant for sickle cell disease is safe and effective.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"89 ","pages":"Article 102179"},"PeriodicalIF":1.6,"publicationDate":"2025-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143180721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low-dose emapalumab combined with chemotherapy for adult patients with Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis","authors":"Wenjuan Zhu ,&nbsp;Fei Zhou ,&nbsp;Yue Song ,&nbsp;Shiyuan Zhou ,&nbsp;Feng Du ,&nbsp;Qian Zhu ,&nbsp;Ziyi Wang ,&nbsp;Liyun Bai ,&nbsp;Jianhong Fu ,&nbsp;Xiao Ma ,&nbsp;Xiaojin Wu ,&nbsp;Xuefeng He","doi":"10.1016/j.trim.2024.102162","DOIUrl":"10.1016/j.trim.2024.102162","url":null,"abstract":"<div><div>Hemophagocytic lymphohistiocytosis (HLH) is a severe disorder with poor clinical outcomes. Use of emapalumab, an IFN-γ inhibitor, enables primary HLH control in over 85 % of affected children. However, data on emapalumab use for Epstein–Barr virus-associated HLH (EBV-HLH) are limited. This report presents the cases of three patients with EBV-HLH, highlighting the successful integration of low-dose emapalumab in combination with chemotherapy as a novel therapeutic approach for patients diagnosed with EBV-HLH. This regimen resulted in rapid disease symptom control and hematological parameter improvement and facilitated successful stem cell transplantation. This report highlights the potential of low-dose emapalumab combined with chemotherapy as an effective bridging therapy to allogenic hematopoietic stem cell transplantation in EBV-HLH patients.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"88 ","pages":"Article 102162"},"PeriodicalIF":1.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142886031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proliferating cell nuclear antigen (PCNA) expression and serum IL-8 product in leiomyomas","authors":"Huda Sadoon Jassim AlBiaty ,&nbsp;Hind H. Al-Ammiri ,&nbsp;Ali yhea Salman","doi":"10.1016/j.trim.2024.102160","DOIUrl":"10.1016/j.trim.2024.102160","url":null,"abstract":"<div><h3>Background</h3><div>The most prevalent neoplasms of the female genital tract are uterine leiomyomas, a uterine fibroid which rarely turn into cancer. We examined the levels of proliferating cell nuclear antigen (PCNA) and interleukin-8 (IL-8) in female patients with Leiomyomas.</div></div><div><h3>Methods</h3><div>The presence of PCNA and IL-8 were measured in 28 females with Leiomyoma and 20 healthy controls. Tissue PCNA levels were measured by immunohistochemistry (IHC) method and serum IL-8 levels were measured by an ELISA technique. Age and menopausal stage on Leiomyoma development were also examined.</div></div><div><h3>Results</h3><div>Forty-eight Iraqi women were divided into 28 uterine Leiomyoma patients of whom leiomyoma tissues, adjacent myometrium and serum samples were collected during hysterectomy. Serum samples were collected from 28 patients and 20 female controls. PCNA was positively expressed in 11 out of 28 (39.2 %) leiomyoma tissues; all 20 normal myometrium were negative. The presence of PCNA was unrelated to age and menopausal stage. The mean level of serum IL-8 was elevated significantly in patients (140 pg/ml) compared to that of control (60 pg/ml; <em>P</em> &lt; 0.05). The IL −8 levels were increased in postmenopausal stage.</div></div><div><h3>Conclusions</h3><div>Each PCNA; IL-8 showed significantly elevated levels in patients with Leiomyoma.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"88 ","pages":"Article 102160"},"PeriodicalIF":1.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142795224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunoglobulin-like receptor genotype-associated protection from cytomegalovirus infection after liver transplantation","authors":"Shuxian Wang ,&nbsp;Bo He ,&nbsp;Huan Liu ,&nbsp;Imran Muhammad ,&nbsp;Jinzhen Cai ,&nbsp;Feng Wang","doi":"10.1016/j.trim.2024.102171","DOIUrl":"10.1016/j.trim.2024.102171","url":null,"abstract":"<div><h3>Background</h3><div>Cytomegalovirus (CMV) is a common clinical infection especially after organ transplantation and threaten the survival of recipients. Natural killer (NK) cells play an important role in the process of CMV infection. In this study, we want to explore that if the different of killer immunoglobulin-like receptors (KIRs) of NK cells could affect CMV infection.</div></div><div><h3>Methods</h3><div>We study a cohort of 447 recipients after liver transplantation in our center. KIR-SSO Genotyping kit was used to detect the activated and inhibitory KIR genes. We determine the high-risk factors for CMV infection, and based on the KIR genotype, the recipients are divided into different groups, then the rate of CMV infection was analyzed.</div></div><div><h3>Results</h3><div>CMV infection occurred in 32/447 (7.2 %) patients in the first year after the transplant surgery. We find that recipient age, Body Mass Index (BMI), Model for End-Stage Liver Disease (MELD) score, intubation time, and occurrence of Early Allograft Dysfunction (EAD) are high-risk factors for CMV infection. Comparing with the CMV-DNA turned negative, the percentage of lymphocyte, as well as the number of lymphocytes and CD4⁺ lymphocytes decreased when the period of receipts' CMV-DNA tested positive. The rate of CMV infection in Tel-B/X genotype group is significantly lower than A/A genotype group.</div></div><div><h3>Conclusions</h3><div>Our data indicates that KIR genes can affect CMV infection and provide potential clinical value following liver transplantation.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"88 ","pages":"Article 102171"},"PeriodicalIF":1.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interferon gamma release assay has potential in the prediction of chronic graft-versus-host disease in recipients of myeloablative allogeneic hematopoietic stem cell transplantation with post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","authors":"Markéta Šťastná-Marková ,&nbsp;Pavla Pecherková ,&nbsp;Šárka Němečková ,&nbsp;Jitka Kryštofová ,&nbsp;Šárka Vaníková ,&nbsp;Jan Vydra ,&nbsp;Kateřina Roubalová","doi":"10.1016/j.trim.2024.102166","DOIUrl":"10.1016/j.trim.2024.102166","url":null,"abstract":"<div><h3>Background</h3><div>The rate of immune reconstitution after allogeneic hematopoietic stem cell transplantation (allo-HSCT) plays the principal role in the development of serious post-transplant complications. However, the post-transplantation course has a significant impact on shaping the immune system of the recipient, per se, thus representing risk factors for subsequent unfavorable outcomes. The predictive power of an interferon gamma (IFNγ) release assay (IGRA) on graft-versus-host disease (GVHD) or hematological relapse in recipients of allo-HSCT treated with post-transplantation cyclophosphamide and the impact of these complications on the restoration of cellular immune responsiveness was evaluated.</div></div><div><h3>Study design</h3><div>A prospective observational study in which 62 adult patients with myeloid hematological malignancies who underwent allo-HSCT with a myeloablative conditioning regimen combined with post-transplantation cyclophosphamide were enrolled. Clinical data were collected and the IGRA was performed before commencement of the conditioning regimen and for 12 months post-allo-HSCT. Multivariate Cox regression and logistic regression models with backward stepwise analyses were used to calculate the predictive values for acute or chronic GVHD, or hematological relapse.</div></div><div><h3>Results</h3><div>Pre-transplantation and early post-transplantation IGRA values and other selected covariables (age, diagnosis, relapse risk, conditioning type, pre-T lymphocyte count, and donor sex), enabled prediction of the 12-month incidence of chronic GVHD with positive and negative predictive values of 75 % and 88 %, respectively. However, the IGRA did not improve the predictive value for acute GVHD or hematological relapse. Patients with myelodysplastic syndrome (MDS) had a significantly lower pre-transplant IGRA value (<em>p</em> = 0.021) and a delayed IFNγ response in IGRA, post-HSCT, than patients with acute myeloid leukemia (AML) (<em>p</em> = 0.015 and <em>p</em> = 0.0063 for 3 and 4 months post-HSCT, respectively).</div></div><div><h3>Conclusions</h3><div>The IGRA can be used to monitor the recovery of total cellular immunity, post-HSCT and it has shown potential for use in personalized post-transplantation care. In the multivariate backward stepwise logistic regression model, pre-and early post-transplantation IGRA values showed potential for predicting chronic GVHD. Patients with MDS had a significantly lower pre-transplantation IGRA value and delayed IFNγ response in IGRA, post-HSCT, than patients with AML.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"88 ","pages":"Article 102166"},"PeriodicalIF":1.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142882837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Severe SARS-CoV-2 infection is associated with increased risk of De novo HLA antibody production in lung transplant recipients: Single-center study","authors":"Sadia Z. Shah ,&nbsp;Zeying Du ,&nbsp;Kamal El Jack ,&nbsp;Si M. Pham ,&nbsp;Mohamed Elrefaei","doi":"10.1016/j.trim.2024.102161","DOIUrl":"10.1016/j.trim.2024.102161","url":null,"abstract":"<div><h3>The purpose</h3><div>The COVID-19 pandemic has led to significant morbidity and mortality in lung transplant recipients (LTR). Respiratory viral infections may be associated with de-novo HLA donor-specific antibody (DSA) production and impact lung transplant outcomes. Since one of the immunomodulation strategies post-SARS-CoV-2 infection in LTR include decreasing or holding anti-metabolites, concerns have been raised for higher incidence of de-novo DSA production in LTR.</div></div><div><h3>Methods</h3><div>We performed a retrospective chart review of 63 consecutive LTR diagnosed with COVID-19 to investigate this concern. COVID-19 disease severity was divided into 3 groups: mild, moderate, and severe. Mild disease was defined as patients with COVID-19 diagnosis who were stable enough to be treated as out-patients. Moderate disease was defined as patients who required admission to the hospital and were on less than 10 l of oxygen at rest. Severe disease was identified as patients who required hospitalization and were on more than 10 l of oxygen with or without mechanical ventilation or extra corporal membrane oxygenation (ECMO). Groups were compared using the Kruskal-Wallis test. A total of 11, 43, and 9 LTR were diagnosed with mild, moderate, and severe COVID-19 respectively.</div></div><div><h3>Results</h3><div>We observed no significant differences in the CPRA pre-COVID-19 compared to 1 and 6 months post-COVID-19 diagnosis in 6/11 (54.5 %), 18/43 (41.8 %), and 6/9 (66.9 %) LTR with mild (<em>p</em> = 0.66), moderate (<em>p</em> = 0.74), and severe (<em>p</em> = 0.22) COVID-19 respectively. HLA class I and II DSA were detected pre-COVID-19 diagnosis and persisted with no significant differences in the median MFI levels at 1 and 6 months post-COVID-19 diagnosis in 2/11 (<em>p</em> = 0.93), 7/43 (<em>p</em> = 0.71), and 0/9 LTR with mild, moderate, and severe COVID-19 respectively. De-novo HLA DSA were detected within 6 months post-COVID-19 diagnosis in 0/11 (0 %), 1/43 (2.3 %), and 3/9 (33.3 %%) LTR with mild, moderate, and severe COVID-19 respectively (<em>p</em> = 0.001).</div></div><div><h3>Conclusion</h3><div>Severe COVID-19 may be associated with increased risk of de novo HLA DSA production resulting in allograft dysfunction.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"88 ","pages":"Article 102161"},"PeriodicalIF":1.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142792590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression patterns of Galectin-3 and NLRP3 in Chagas reactivation and graft damage in heart transplants","authors":"Caio E. Gullo ,&nbsp;Diego D. dos Santos ,&nbsp;Mab P. Corrêa ,&nbsp;Cristiane D. Gil ,&nbsp;Reinaldo B. Bestetti","doi":"10.1016/j.trim.2024.102159","DOIUrl":"10.1016/j.trim.2024.102159","url":null,"abstract":"<div><h3>Objective</h3><div>This study aimed to assess the expression patterns of galectin-3 (Gal-3) and NLRP3 in heart transplant recipients according to the presence of reactivated <em>Trypanosoma cruzi</em> infection or allograft rejection in Chagas and non-Chagas heart transplant recipients.</div></div><div><h3>Methods</h3><div>Gal-3 and NLRP3 expression levels were analyzed in endomyocardial biopsies from 31 heart transplant recipients, including 16 patients with chronic Chagas disease (ChD) and 15 without ChD. Samples were evaluated during periods of graft rejection or ChD reactivation, characterized by intense myocardial cellular infiltrate, and after remission of the infiltrate, classified by histopathological severity. The transcriptional levels of genes encoding Gal-3, NLRP3, Asc, caspase-1, and IL-1β were identified using the GEO2T tool across different experimental conditions.</div></div><div><h3>Results</h3><div>Gal-3 expression was lower in the myocardial infiltrate of ChD patients compared to non-ChD patients (<em>p</em> &lt; 0.0001), whereas NLRP3 positivity was higher in ChD patients (<em>p</em> &lt; 0.05). In a murine model of <em>T. cruzi</em> infection, elevated Gal-3 mRNA and NLRP3 inflammasome levels were observed in myocardial interstitial cells (<em>p</em> &lt; 0.05). Peripheral blood mononuclear cells and cells from rodent cardiac allografts showed increased Gal-3 mRNA and NLRP3 levels compared to non-transplanted and rodent cardiac isografts (<em>p</em> &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>Our findings suggest that Gal-3 and NLRP3 may be important biomarkers for differentiating heart transplant recipients with and without ChD regarding the myocardial immunological processes.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"88 ","pages":"Article 102159"},"PeriodicalIF":1.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142792589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}